PharmaCyte Biotech’s Cell-in-a-Box® Cancer Treatment Shows “Complete Tumor Remission”

PharmaCyte Biotech (OTCMKTS:PMCB) announced that its signature live-cell encapsulation technology, Cell-in-a-Box®, when used with low doses of the anticancer drug ifosfamide was able to produce “complete tumor remission in all animals” that received the treatment on days 2-6 of a previously published preclinical study.

As quoted in the press release:

It was a study that used a colon cancer model to treat malignant ascites, a fluid that is common with abdominal cancers like pancreatic, colon, ovarian and liver cancer that accumulates in the abdominal cavity and causes painful swelling of the stomach. In PharmaCyte Biotech’s corporate video (www.PharmaCyte.com/media), renowned gastroenterologist and oncologist, Dr. Matthias Löhr of the famed Karolinska Institute in Stockholm, Sweden, says that he and a team of doctors and researchers found that they “could virtually cure malignant ascites” in this study.

Readers can find the published preclinical study in Cancer Gene Therapy here: https://www.nature.com/cgt/journal/v13/n1/full/7700849a.html

The preclinical study, commissioned by Bavarian Nordic, used “targeted chemotherapy” to treat malignant ascites just as PharmaCyte biotech does. In the study, words like “complete tumor remission” and “cure” were used to describe the results, so why didn’t Bavarian Nordic continue on with its work?

Well, at the time of the study, Bavarian Nordic, the forerunner to Austrianova, had three in-house technologies: (i) the encapsulation technology; (ii) a retroviral vector technology; and (iii) a poxvirus based delivery platform. As a result of the attacks of 9/11 in the United States, Bavarian Nordic decided to focus strategically on the development of a smallpox vaccine based on its poxvirus platform and chose to divest the other two technologies, which eventually were moved into Austrianova.

Austrianova GmbH, based in Europe then, was focused on one big indication — namely pancreatic cancer. Executives at Austrianova made the decision then to go straight into a pivotal Phase 3 clinical trial in pancreatic cancer, which would have cost the biotech about $40 million. Austrianova was also working on setting up the GMP manufacturing facility in Frankfurt, Germany, and the firm was working on a veterinary clinical trial in mammary cancer.

Click here to read the full PharmaCyte Biotech (OTCMKTS:PMCB) press release.